COVID-19 tracker: Moderna seeks vaccine nod for young children; Merck’s antiviral pulls in $3.2Bnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: SK bioscience, GSK vaccine passes phase 3; Novavax gets FDA adcomm datenews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Poland has no rationale to exit Pfizer supply deal, European Commission saysnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Pfizer’s Paxlovid does not pan out as a preventive therapynews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Moderna trumpets vaccine boosters as Regeneron’s antibody cocktail sales lapsenews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Medicago’s phase 3 vaccine results published in NEJMnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Researchers want to test Pfizer’s Paxlovid in long COVIDnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Boosters will be the next major vaccine market, execs saynews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Third Pfizer jab significantly boosts protection from infection, study findsnews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
COVID-19 tracker: Pfizer working on a vaccine that can last a year or morenews2022-04-13T18:42:33+00:00April 13th, 2022|Fierce Pharma|
